Skip to main content

Table 2 Bloodstream infection characteristics

From: DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci

 

N = 49

Age, median (IQR)

67 (50–75)

Male, n (%)

36 (73.5)

Charlson index, n (%)

2 (1–4)

Type of infection, n (%)

 Complicated bloodstream infection

34 (69.4)

 Uncomplicated bloodstream infection

15 (30.6)

Causative organism, n (%)

 MSSA

15 (30.6)

 MRSA

9 (18.4)

 CNS

17 (34.7)

 E. faecalis

1 (2)

 E. faecium

2 (4.1)

 Streptococcus

2 (4.1)

 Other

1 (2)

 No isolation

2 (4.1)

 Days of prior AB therapy, median (IQR)

8 (0–15)

 Prior antibiotic therapy, n (%)

46 (93.9)

 Daptomycin

22 (44.9)

 Ceftriaxone

10 (20.4)

 Linezolid

9 (18.4)

 Vancomycin

11 (22.4)

Reason for DBV administration, n (%)

 Facilitate discharge

38 (77.6)

 Prior treatment failure

1 (2)

 Toxicity

2 (4)

DBV dose, n (%)

 1000 mg (1 day), 500 mg (8 days)

14 (28.6)

 1000 mg 1 day

11 (22.4)

 1500 mg 1 day

21 (42.9)

 Other

3 (6.1)

 DBV-covered treatment days (IQR)

14 (14)

 Clinical cure, n (%)

49 (100)

Microbiological cure

 Follow-up blood cultures, n (%)

36 (73.5)

 Negative follow-up blood cultures

35 (97.2)

 Death related to bloodstream infection, n (%)

0

 Relapse, n (%)

0

 Readmission for different reason

1 (2)

 Reduction in days of hospital stay (IQR)

14 (7–14)

 Total reduction, days

636